garetosmab · Pasatru
Monoclonal antibody
Evidence outlook
Approved: Fibrodysplasia Ossificans Progressiva (label: Adults with FOP: reduces new heterotopic ossification lesions and flare-ups)
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Obesity · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
OPTIMA NCT05394116 · Fibrodysplasia Ossificans Progressiva The trial randomized participants to high-dose garetosmab, low-dose garetosmab, or placebo with full quadruple blinding (patients, care providers, investigators, and outcomes assessors all masked), which minimizes bias in how the treatment effect was measured. The primary endpoint -- number of new heterotopic ossification lesions detected by whole-body CT -- is an objective, disease-defining radiographic measure for FOP, not a soft biomarker. An outside report indicates this primary comparison was met, with garetosmab reducing new lesion counts by roughly 90-94% relative to placebo, a large and clearly favorable separation. Registry: NCT05394116 | 3 | Number of new HO lesions (At Week 56); Incidence and severity of treatment-emergent adverse events of special interest (AESIs) (Baseline to Week 56) 2025-07-17 | OPTIMA (NCT05394116), primary endpoint new HO lesions by whole-body CT at week 56: 94% reduction with garetosmab 3 mg/kg vs placebo; 90% reduction with garetosmab 10 mg/kg vs placebo | Reliable signal | link ↗ |
View 1 more trial
OPTIMA-2 NCT07559513 · Fibrodysplasia Ossificans Progressiva (FOP) Registry: NCT07559513 | 3 | Occurrence of Treatment-Emergent Adverse Event (TEAEs) (Baseline to week 28); Occurrence of TEAEs (Baseline to week 56); Severity of TEAEs (Baseline to week 28); Severity of TEAEs (Baseline to week 56); Concentrations of functional garetosmab in serum (Through week 56) 2030-07-08 | In progress: results expected 8 Jul 2030 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Fibrodysplasia Ossificans Progressiva: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Garetosmab (Pasatru): this drug | Approved | Monoclonal antibody | Activin A | Reliable signal | NCT05394116: OPTIMA (NCT05394116), primary endpoint new HO lesions by whole-body CT at week 56: 94% reduction with garetosmab 3 mg/kg vs placebo; 90% reduction with garetosmab 10 mg/kg vs placebo | |
| Andecaliximab | Phase 2/3 | Monoclonal antibody | Matrix metalloproteinase 9 (MMP-9), Matrix metalloproteinase-9 (MMP-9) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Pasatru (garetosmab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2030 (1)
July 2030 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent